GlaxoSmithKline plc (LON:GSK) had its price objective decreased by investment analysts at Jefferies Group from GBX 1,950 ($24.36) to GBX 1,850 ($23.11) in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective would suggest a potential upside of 20.33% from the stock’s previous close.

Several other research analysts have also recently issued reports on GSK. Credit Suisse Group AG reissued a “neutral” rating and issued a GBX 1,800 ($22.49) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 14th. BNP Paribas set a GBX 1,530 ($19.12) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Thursday, July 14th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, July 19th. Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 27th. Finally, S&P Global Inc. set a GBX 1,650 ($20.61) price target on GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Wednesday, July 27th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have issued a buy rating to the company. GlaxoSmithKline plc has a consensus rating of “Hold” and an average price target of GBX 1,719.38 ($21.48).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1545.50 on Friday. The firm has a 50-day moving average price of GBX 1,636.86 and a 200 day moving average price of GBX 1,584.58. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56. The stock’s market cap is GBX 75.20 billion.

The business also recently disclosed a dividend, which will be paid on Thursday, January 12th. Stockholders of record on Thursday, November 3rd will be issued a dividend of GBX 19 ($0.24) per share. This represents a dividend yield of 1.17%. The ex-dividend date is Thursday, November 3rd.

In other news, insider Sir Andrew P. Witty sold 10,000 shares of the stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($20.44), for a total transaction of £163,600 ($204,397.80). Also, insider Manvinder Singh Banga acquired 1,750 shares of the stock in a transaction dated Wednesday, October 26th. The shares were bought at an average cost of GBX 1,643 ($20.53) per share, for a total transaction of £28,752.50 ($35,922.66).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.